Clients

OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

ONCS
Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Client News

  1. Aug 27 2020 OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
  2. Aug 25 2020 OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020
  3. Aug 16 2020 OncoSec Medical Incorporated Announces Pricing of Public Offering
  4. Aug 14 2020 OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
  5. Aug 10 2020 OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020